Please SUPPORT S. 413 / H.R. 1038
Medicare Part D Pharmacy “DIR” Fees
Ban on Retroactive Fees Would Lower Costs, Help Seniors, and Preserve Pharmacy Access
Part D plan sponsors and Pharmacy Benefit Managers (PBMs) extract DIR (Direct and Indirect Remuneration) fees from community pharmacies. Nearly all pharmacy DIR fees are clawed back retroactively months after claims have been paid to pharmacies rather than deducted from the claims at the time they are processed. This reimbursement creates uncertainty for community pharmacists and makes it extremely difficult to operate their small businesses. Moreover, in January 2017 the Centers for Medicare & Medicaid Services (CMS) warned the rise in pharmacy DIR fees has increased Medicare costs to the government and patients, partially by forcing more beneficiaries into the coverage gap (or “donut hole”).
Prohibit retroactive DIR fees on pharmacies.
The “Improving Transparency and Accuracy in Medicare Part D Drug Spending Act,” S. 413 / H.R. 1038 will prohibit Medicare Part D plan sponsors/PBMs from retroactively reducing payment on clean claims submitted by pharmacies under Medicare Part D, which would:
- Lower Medicare costs for taxpayers. Wakely Consulting Group concluded that enactment of S. 413/H.R. 1038 would save the federal government $3.4 billion over the next ten years .
- Boost transparency in drug pricing. Prohibiting these retroactive pharmacy fees will make Medicare Plan Finder more accurate and allow better CMS oversight.
- Give seniors reduced cost-sharing and greater budget predictability. Beneficiaries who use their drug plan to fill prescriptions are punished the most by pharmacy DIR fees. This is because retroactive fees lead to inflated drug costs that are the basis for beneficiary cost-sharing amounts.
- Preserve access to independent community pharmacies. Locally owned pharmacies provide enhanced patient care, and are often located in underserved rural and inner-city areas. The number of U.S. independent community pharmacies has declined the past five years and a recent study estimated 3 million rural residents are at risk of losing the only pharmacy in their community with the next nearest pharmacy over 10 miles away,  a trend exacerbated by DIR.
- Address the concerns of CMS and MedPAC. CMS has noted  “variations in the treatment of costs and price concessions affect beneficiary cost sharing, CMS payments to plans, federal reinsurance and low income cost-sharing (LICS) subsidies, manufacturer coverage gap discount payments, and plan bids.” According to MedPAC's 2015 Report to Congress, “MedPAC sees insurers gaming the system to hold premiums down and maximize enrollment.”
S. 413 / H.R. 1038...
Will Not Lead to unaffordable Medicare Part D premiums. The current DIR system, while slightly lowering beneficiary premiums, drives up patient costs at the pharmacy. The only winners are PBMs and the rare Part D beneficiary who pays premiums but never fills a prescription.
Will Not Ban “pay-for-performance” programs. S. 413 / H.R. 1038 will allow health plans and PBMs to reward pharmacies for achieving quality based metrics.
Please contact your representatives today
Ask your representatives to co-sponsor legislation in both the U.S. Senate and the House of Representatives that would curb abusive DIR fees: Medicare Part D Pharmacy “DIR” Fees – S. 413 / H.R. 1038. Click here to send a letter or call the numbers listed below:
US Representative Scott Tipton: Durango, (970) 259-1490
US Senator Cory Gardner: Durango, 970-415-7416
US Senator Michael Bennett: Durango, (970) 259-1710
Download your copy of The PBM Story to learn more.
 CMS, “Medicare Part D –Direct and Indirect Remuneration,”
 Wakely Consulting Group analysis of S. 413/H.R. 1038
 RUPRI Center for Rural Health Policy Analysis. “Issues Confronting Rural Pharmacies after a Decade of Medicare Part D.” April, 2017
 CMS, “Direct and Indirect Remuneration (DIR) and Pharmacy Price Concessions”